MODERN
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
- NCT05987241 ↗
- Recruiting
- National Cancer Institute (NCI)
- Focused
We haven't built an HCP commentary report on MODERN (nivolumab and relatlimab in Muscle Invasive Bladder Urothelial Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MODERN so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
- Phase
- Phase 2/Phase 3
- Status
- Recruiting
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma; Muscle Invasive Renal Pelvis Urothelial Carcinoma; Muscle Invasive Ureter Urothelial Carcinoma; Muscle Invasive Urethral Urothelial Carcinoma; Stage II Bladder Urothelial Carcinoma AJCC v6 and v7; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7; Stage IV Bladder Urothelial Carcinoma AJCC v7
- Interventions
- Biospecimen Collection; cfDNA or ctDNA Measurement; Computed Tomography; Cystoscopy; Magnetic Resonance Imaging; Nivolumab; Questionnaire Administration; Relatlimab
- Arms
- Cohort A, Arm I (nivolumab) · Active comparator
- Cohort A, Arm II (nivolumab, relatlimab) · Experimental
- Cohort B, Arm III (nivolumab) · Active comparator
- Cohort B, Arm IV (ctDNA surveillance, nivolumab) · Experimental
- Enrollment
- 992 (estimated)
- Primary outcomes
- Proportion of patients who are circulating tumor DNA negative (ctDNA[-]) (Cohort A Phase II)
- Overall survival (OS) (Cohort A Phase III)
- Disease-Free Survival (DFS) (Cohort B)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Feb 2, 2024
- Primary completion
- Sep 2, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT05987241 · updated Oct 27, 2026